Jean-Pierre Morello, Ph.D.

Affiliations: 
2001 Université de Montréal, Montréal, Canada 
Google:
"Jean-Pierre Morello"
Mean distance: 17.4 (cluster 11)
 
SNBCP

Parents

Sign in to add mentor
Michel Bouvier grad student 2001 Université de Montréal
 (Mutations leading to misfolding and endoplasmic reticulum retention of the V2 vasopressin receptor: Assessing pharmacologically-assisted folding and targeting.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Bernier V, Morello JP, Zarruk A, et al. (2006) Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : Jasn. 17: 232-43
Gervais FG, Morello JP, Beaulieu C, et al. (2005) Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Molecular Pharmacology. 67: 1834-9
Petäjä-Repo UE, Hogue M, Bhalla S, et al. (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. The Embo Journal. 21: 1628-37
Morello JP, Salahpour A, Petäjä-Repo UE, et al. (2001) Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. Biochemistry. 40: 6766-75
Morello JP, Bichet DG. (2001) Nephrogenic diabetes insipidus. Annual Review of Physiology. 63: 607-30
Morello JP, Petäjä-Repo UE, Bichet DG, et al. (2000) Pharmacological chaperones: a new twist on receptor folding. Trends in Pharmacological Sciences. 21: 466-9
Morello JP, Salahpour A, Laperrière A, et al. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. The Journal of Clinical Investigation. 105: 887-95
Morello J, Bernier V, Bouvier M, et al. (2000) Des chaperons pharmacologiques pour corriger le diabète insipide néphrogénique ? MéDecine/Sciences. 16: 1109
Morello JP, Bouvier M. (1996) Palmitoylation: a post-translational modification that regulates signalling from G-protein coupled receptors. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 74: 449-57
Hebert TE, Moffett S, Morello JP, et al. (1996) A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. The Journal of Biological Chemistry. 271: 16384-92
See more...